results
Last reviewed 01/2018
Treatment with ramipril resulted in the following risk reductions:
- 25% (p=0.0004) for combined primary outcome
- 22% for MI
- 33% for stroke
- 37% for cardiovascular death
- 17% revascularisation
- 24% (p=0.027) for overt nephropathy